

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number  
**WO 2004/055006 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 401/12**,  
401/14, 403/12; 403/14, A61K 31/497, 31/496, 31/5377,  
A61P 25/00, 3/10, 5/48, 15/18, 17/14

SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/SE2003/001956

(84) Designated States (*regional*): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:  
15 December 2003 (15.12.2003)

(25) Filing Language: English

**Declaration under Rule 4.17:**

(26) Publication Language: English

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,  
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,  
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,  
LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG)

(30) Priority Data:  
0203752-1 17 December 2002 (17.12.2002) SE

(71) Applicant (*for all designated States except US*): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BERG, Ste-  
fan** [SE/SE]; AstraZeneca R & D Södertälje, S-151  
85 Södertälje (SE). **HELLBERG, Sven** [SE/SE]; As-  
traZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-  
traZeneca AB, S-151 85 Södertälje (SE).

**Published:**

— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,  
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NOBEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3

(57) Abstract: The present invention relates to new compounds, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, such as provide compounds having a selective inhibiting effect at GSK3.



WO 2004/055006 A1

10/539546

1

JC05 Rec'd PGT/PTO 16 JUN 2005

Novel compound having selective inhibiting effect at GSK3.

5

## FIELD OF THE INVENTION

The present invention relates to new compounds of formula I, as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, to pharmaceutical formulations containing said compounds and to the use of said compounds in therapy. The present invention further relates to a process for the preparation of compounds of formula I and to new intermediates used therein.

## 15 BACKGROUND OF THE INVENTION

Glycogen synthase kinase 3 (GSK3) is a serine / threonine protein kinase composed of two isoforms ( $\alpha$  and  $\beta$ ), which are encoded by distinct genes but are highly homologous within the catalytic domain. GSK3 is highly expressed in the central and peripheral nervous system. GSK3 phosphorylates several substrates including tau,  $\beta$ -catenin, glycogen synthase, pyruvate dehydrogenase and elongation initiation factor 2b (eIF2b). Insulin and growth factors activate protein kinase B, which phosphorylates GSK3 on serine 9 residue and inactivates it.

## 25 *Alzheimer's Disease (AD) dementias, and tauopathies.*

AD is characterized by cognitive decline, cholinergic dysfunction and neuronal death, neurofibrillary tangles and senile plaques consisting of amyloid- $\beta$  deposits. The sequence of these events in AD is unclear, but is believed to be related. Glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) or Tau ( $\tau$ ) phosphorylating kinase selectively phosphorylates the microtubule associated protein  $\tau$  in neurons at sites that are hyperphosphorylated in AD brains. Hyperphosphorylated protein  $\tau$  has lower affinity for microtubules and accumulates as paired helical filaments, which are the main components that constitute neurofibrillary

30

tangles and neuropil threads in AD brains. This results in depolymerization of microtubules, which leads to dying back of axons and neuritic dystrophy. Neurofibrillary tangles are consistently found in diseases such as AD, amyotrophic lateral sclerosis, parkinsonism-dementia of Gaum, corticobasal degeneration, dementia pugilistica and head trauma, Down's syndrome, postencephalatic parkinsonism, progressive supranuclear palsy, Niemann-Pick's Disease and Pick's Disease. Addition of amyloid- $\beta$  to primary hippocampal cultures results in hyperphosphorylation of  $\tau$  and a paired helical filaments-like state via induction of GSK3 $\beta$  activity, followed by disruption of axonal transport and neuronal death (Imahori and Uchida., J. Biochem 121:179-188, 1997). GSK3 $\beta$  preferentially labels neurofibrillary tangles and has been shown to be active in pre-tangle neurons in AD brains. GSK3 protein levels are also increased by 50% in brain tissue from AD patients. Furthermore, GSK3 $\beta$  phosphorylates pyruvate dehydrogenase, a key enzyme in the glycolytic pathway and prevents the conversion of pyruvate to acetyl-Co-A (Hoshi et al., PNAS 93:2719-2723, 1996). Acetyl-Co-A is critical for the synthesis of acetylcholine, a neurotransmitter with cognitive functions. Thus, GSK3 $\beta$  inhibition may have beneficial effects in progression as well as the cognitive deficits associated with Alzheimer's disease and other above-referred to diseases.

#### *Chronic and Acute Neurodegenerative Diseases.*

Growth factor mediated activation of the PI3K /Akt pathway has been shown to play a key role in neuronal survival. The activation of this pathway results in GSK3 $\beta$  inhibition. Recent studies (Bhat et. al., PNAS 97:11074-11079 (2000)) indicate that GSK3 $\beta$  activity is increased in cellular and animal models of neurodegeneration such as cerebral ischemia or after growth factor deprivation. For example, the active site phosphorylation was increased in neurons vulnerable to apoptosis, a type of cell death commonly thought to occur in chronic and acute degenerative diseases such as Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's Disease and HIV dementia, ischemic stroke and head trauma. Lithium was neuroprotective in inhibiting apoptosis in cells and in the brain at doses that resulted in the inhibition of GSK3 $\beta$ . Thus GSK3 $\beta$  inhibitors could be useful in attenuating the course of neurodegenerative diseases.

*Bipolar Disorders (BD)*

Bipolar Disorders are characterised by manic episodes and depressive episodes. Lithium has been used to treat BD based on its mood stabilising effects. The disadvantage of  
5 lithium is the narrow therapeutic window and the danger of overdosing that can lead to lithium intoxication. The recent discovery that lithium inhibits GSK3 at therapeutic concentrations has raised the possibility that this enzyme represents a key target of lithium's action in the brain (Stambolic et al., Curr. Biol. 6:1664-1668, 1996; Klein and Melton; PNAS 93:8455-8459, 1996). Inhibition of GSK3 $\beta$  may therefore be of therapeutic  
10 relevance in the treatment of BD as well as in AD patients that have affective disorders.

*Schizophrenia*

GSK3 is involved in signal transduction cascades of multiple cellular processes, particularly during neural development. Kozlovsky et al (Am J Psychiatry 2000  
15 May;157(5):831-3) found that GSK3 $\beta$  levels were 41% lower in the schizophrenic patients than in comparison subjects. This study indicates that schizophrenia involves neurodevelopmental pathology and that abnormal GSK3 regulation could play a role in schizophrenia. Furthermore, reduced  $\beta$ -catenin levels have been reported in patients exhibiting schizophrenia (Cotter et al., Neuroreport 9:1379-1383 (1998)).

20

*Diabetes*

Insulin stimulates glycogen synthesis in skeletal muscles via the dephosphorylation and thus activation of glycogen synthase. Under resting conditions, GSK3 phosphorylates and inactivates glycogen synthase via dephosphorylation. GSK3 is also over-expressed in  
25 muscles from Type II diabetic patients (Nikoulina et al., Diabetes 2000 Feb;49(2):263-71). Inhibition of GSK3 increases the activity of glycogen synthase thereby decreasing glucose levels by its conversion to glycogen. GSK3 inhibition may therefore be of therapeutic relevance in the treatment of Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

30

*Hair Loss*


GSK3 phosphorylates and degrades  $\beta$ -catenin.  $\beta$ -catenin is an effector of the pathway for keratin synthesis.  $\beta$ -catenin stabilisation may lead to increase hair development. Mice expressing a stabilised  $\beta$ -catenin by mutation of sites phosphorylated by GSK3 undergo a process resembling de novo hair morphogenesis (Gat et al., Cell 1998 Nov 25;95 (5):605-14)). The new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis. Thus GSK3 inhibition may offer treatment for baldness.

*Oral contraceptives*

Vijayaraghavan et al. (Biol Reprod 2000 Jun; 62 (6):1647-54) reported that GSK3 is high in motile versus immotile sperm. Immunocytochemistry revealed that GSK3 is present in the flagellum and the anterior portion of the sperm head. These data suggest that GSK3 could be a key element underlying motility initiation in the epididymis and regulation of mature sperm function. Inhibitors of GSK3 could be useful as contraceptives for males.

## DISCLOSURE OF THE INVENTION

The object of the present invention is to provide compounds having a selective inhibiting effect at GSK3 as well as having a good bioavailability. The compounds fall within the generic formula I:



wherein:

Z is N;

Y is CONR<sup>5</sup>;

X is N;

P is phenyl;

Q is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms  
5 independently selected from N, O or S;

R is selected from C<sub>0-6</sub>alkyl(SO<sub>2</sub>)NR<sup>1</sup>R<sup>2</sup>, C<sub>0-6</sub>alkylCONR<sup>1</sup>R<sup>2</sup> and OC<sub>1-6</sub>alkylNR<sup>1</sup>R<sup>2</sup>;

R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylNR<sup>6</sup>R<sup>7</sup>,

C<sub>1-6</sub>alkylOR<sup>6</sup> and a 5 or 6 membered heterocyclic ring containing one or more heteroatoms  
independently selected from N, O, or S and wherein said C<sub>1-6</sub>alkyl or heterocyclic ring

10 may be optionally substituted by A;

R<sup>1</sup> and R<sup>2</sup> may together form a substituted 5 or 6 membered heterocyclic ring containing  
one or more heteroatoms independently selected from N, O, or S and said heterocyclic ring  
may be optionally substituted by A;

R<sup>3</sup> and R<sup>4</sup> is independently selected from halo, nitro, trifluoromethyl, C<sub>0-6</sub>alkylCN,

15 C<sub>0-6</sub>alkylOR<sup>6</sup>, C<sub>0-6</sub>alkylCONR<sup>6</sup>R<sup>7</sup>, C<sub>0-6</sub>alkylNR<sup>6</sup>(CO)R<sup>7</sup>, C<sub>0-6</sub>alkylCOR<sup>6</sup>,

C<sub>0-6</sub>alkyl(SO<sub>2</sub>)NR<sup>6</sup>R<sup>7</sup>;

m is 0 or 1;

n is 0 or 1;

R<sup>5</sup> is hydrogen;

20 R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen and C<sub>1-6</sub>alkyl;

R<sup>6</sup> and R<sup>7</sup> may together form a substituted 5 or 6 membered heterocyclic ring containing  
one or more heteroatoms independently selected from N, O, or S one or more heteroatoms  
independently selected from N, O or S and said heterocyclic ring may be optionally  
substituted by A;

25 A is C<sub>1-6</sub>alkyl;

as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

In one aspect of the invention the following compounds are provided:

3-Amino-N-(3-nitrophenyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

30

3-Amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-N-1H-tetrazol-5-ylpyrazine-2-  
carboxamide;

*N*-[3-(Acetylamino)phenyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide;

5 3-Amino-*N*-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide;

as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof;

10 3-Amino-6-[4-([(1*R*)-2-methoxy-1-methylethyl]amino)sulfonyl]phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-6-[4-([(1*S*)-2-methoxy-1-methylethyl]amino)sulfonyl]phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

15 3-Amino-*N*-(2-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

20 3-Amino-6-(4-[(2-ethoxyethyl)amino]sulfonyl)phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(4-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

25 3-Amino-*N*-[2-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[3-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

30 3-Amino-*N*-(3-cyanophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

35 3-Amino-*N*-(2-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(3-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

40 3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-1*H*-pyrazol-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[4-(aminocarbonyl)-1*H*-pyrazol-3-yl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

45 3-Amino-*N*-1*H*-imidazol-2-yl-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

5 3-Amino-6-[4-[[[(1-ethyl-3-piperidinyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

10 3-Amino-6-[4-[[[(3-methylbutyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[[[(1*S*)-2-methoxy-1-methylethyl]amino]carbonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

15 3-Amino-*N*-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

20 3-Amino-*N*-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;


*N*-(3-Acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

25 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[3-(trifluoromethyl)phenyl]-2-pyrazinecarboxamide hydrochloride;

or as a free base or an alternative a pharmaceutically acceptable salt, solvate or solvate of a salt thereof;

30

Another aspect of the invention the compounds of formula XIX, which are useful as intermediates in the preparation of compounds of formula I, are provided





wherein R, R<sup>3</sup>, P, X, Z, and m are as defined above, and wherein E and F are a methoxy group or hydrogen and G is a spacer chain containing atoms selected from oxygen and carbon; as a free base or a salt, solvate or solvate of a salt thereof.

- 5 In yet another aspect of the invention the following compounds, which are useful as intermediates in the preparation of compounds of formula I, are provided:

3-Amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-carboxamide;

- 10 1-[(4-Bromophenyl)sulfonyl]pyrrolidine;

4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid;

4-Bromo-*N*-[(1*R*)-2-hydroxy-1-methylethyl]benzenesulfonamide;

- 15 4-Bromo-*N*-[(1*R*)-2-methoxy-1-methylethyl]benzenesulfonamide;

4-Bromo-*N*-[(1*S*)-2-methoxy-1-methylethyl]benzenesulfonamide;

- 20 Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate;

4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid;

Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate;

- 25 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid;

4-[2-(4-Bromo-2-fluorophenoxy)ethyl]morpholine;

- 30 4-Bromo-*N*-(1-ethyl-3-piperidiny)benzenesulfonamide;

4-Bromo-*N,N*-bis(2-methoxyethyl)benzenesulfonamide;

4-Bromo-*N*-(3-methylbutyl)-benzenesulfonamide;

- 35 4-Bromo-*N*-(2-ethoxyethyl)benzenesulfonamide;

Methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene;

- 40 3-{[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene;

4-{5-Amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid;

as a free base or a salt, solvate or solvate of a salt thereof.

Listed below are definitions of various terms used in the specification and claims to  
5 describe the present invention.

For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined', 'defined hereinbefore', 'is as defined above' or 'are as defined above' the said group encompasses the first occurring and broadest definition as  
10 well as each and all of the preferred definitions for that group.

For the avoidance of doubt it is to be understood that in this specification 'C<sub>0-6</sub>' means a carbon group having 0, 1, 2, 3, 4, 5 or 6 carbon atoms.

15 In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl groups. C<sub>1-6</sub>alkyl may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, hexyl.

The term "alkoxy" as used herein, unless stated otherwise includes "alkyl"O groups in  
20 which "alkyl" is as hereinbefore defined. C<sub>1-5</sub>alkoxy may be methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy, t-pentyloxy, neo-pentyloxy.

In this specification, unless stated otherwise, the term "5 or 6 membered heteroaromatic  
25 ring containing one or more heteroatoms independently selected from N, O, or S" may be, but are not limited to, furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl or imidazolyl.

In this specification, unless stated otherwise, the term "5 or 6 membered heterocyclic ring  
30 containing one or more heteroatoms independently selected from N, O, or S" may be, but are not limited to, imidazolidinyl, imidazoliny, morpholinyl, piperazinyl, piperidyl,

piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl or thiomorpholinyl.

In this specification, unless stated otherwise, the term halogen may be fluorine, chlorine,  
5 bromine or iodine. The term Hal in the formulas means halogen.

The present invention relates to the use of compounds of formula I as hereinbefore defined as a free base as well as to the salts, solvates and solvates of salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may  
10 be useful in the production of the compounds of formula I.

Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds, e.g. hydrochlorides of this invention. In addition, a suitable pharmaceutically acceptable salt of the compounds of the invention,  
15 which is sufficiently acidic is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base, which affords a physiologically-acceptable cation.

It will be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present  
20 invention encompasses all such solvated forms which possess the above-mentioned activity.

Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such  
25 diastereoisomers, optical and geometric isomers that possess GSK3 inhibitory activity.

It is to be understood that the present invention relates to any and all tautomeric forms of the compounds of formula I.

30 An object of the invention is to provide compounds of formula I for therapeutic use, especially compounds that are useful for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 (GSK3) in mammals

including man. Particularly, compounds of formula I exhibiting a selective affinity for GSK-3.

It is also an object of the invention to provide compounds with a therapeutic effect after oral administration.


## METHODS OF PREPARATION

Another aspect of the present invention provides a process for preparing a compound of formula I as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.


Throughout the following description of such processes it is understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for example, in "Protective Groups in Organic Synthesis" T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, 1999.

### Methods of preparation of intermediates

The process for the preparation of the intermediates, wherein Y, X, Z, P, Q, R, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, A, m and n are, unless specified otherwise, defined as in formula I, comprises of:




(i) halogenation of a compound of formula **II**, wherein X and Z are N, R<sup>8</sup> is hydrogen, C<sub>1</sub>-<sub>6</sub>alkyl or when R<sup>8</sup> is hydrogen in the form of the acid or a salt such as a sodium salt, to obtain a compound of formula **III**, where Hal is halogen, may be carried out using a suitable halogenating reagent e.g. iodine, bromine, chlorine, halide salts for example ICl, BrCl or HOCl or other suitable halogenation reagents e.g. *N*-bromosuccinimide or phosphorous tribromide. The reaction may be catalysed by metals or acids such as Fe, Cu-salts, acetic acid or sulfuric acid or aided by oxidising agents e.g. nitric acid, hydrogen peroxide or sulfur trioxide. The reaction may be carried out in a suitable solvent such as water, acetic acid or chloroform at a temperature in the range of -70 °C to +100 °C.




(ii) amidation of a compound of formula **III**, wherein X and Z are N, R<sup>8</sup> is C<sub>1</sub>-<sub>6</sub>alkyl to obtain a compound of formula **IV**, wherein Y is CONR<sup>5</sup> and R<sup>4</sup>, Q and m are as defined above may be carried out by treating a compound of formula **III** with the appropriate amine such as a compound of formula **V**, wherein Q is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S, R<sup>4</sup> and m are as defined above. The reaction may be performed neat or using a suitable solvent such as *N,N*-dimethylformamide, methylene chloride or ethyl acetate at a temperature ranging from -25 °C to +150 °C. The reaction may be aided by using a base such as potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene, or an acid such as trimethylaluminum or p-toluenesulfonic acid.

13



(iii) amidation of a compound of formula **III**, wherein  $R^8$  is hydrogen, to obtain a compound of formula **IV**, wherein  $Y$  is  $\text{CONR}^5$ ,  $m$  are as defined above, and  $R^4$  is a substituent that is not susceptible to certain coupling agents, may be performed by activation of a compound of formula **III** by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate, *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate, followed by treatment with the appropriate amine such as a compound of formula **V** in a suitable solvent such as methylene chloride chloroform, acetonitrile or tetrahydrofuran at a reaction temperature between 0 °C and reflux. The reaction may be aided by using a base such as potassium carbonate or a trialkylamine e.g triethylamine or *N*-ethyl-*N,N*-diisopropylamine.

20




(iv) conversion of a compound of formula **III** to a compound of formula **VI**, wherein X and Z are N,  $R^8$  is  $C_{1-6}$ alkyl and R,  $R^3$ , P and n are as defined above, may be carried out by a de-halogen coupling with a suitable compound of formula **XVIa-c**.

- 5 The reaction may be carried out by coupling of a compound of formula **III** with an appropriate aryl boronic acid or a boronic ester of formula **XVIa-c** (the boronic acid or boronic ester may be formed in situ using the compounds of formula **XI**, **XIII**, **XV** or **XXI** and conditions described in (xii)). The reaction may be carried out using a suitable palladium catalyst such as  $Pd(PPh_3)_4$ ,  $Pd(dppf)Cl_2$  or  $Pd(OAc)_2$  with or without a suitable
- 10 ligand such as  $P(tert-butyl)_3$  or 2-(dicyclohexylphosphino)biphenyl in the presence of a suitable base such as an alkylamine e.g. triethylamine, or potassium carbonate, potassium phosphate, sodium carbonate, sodium hydroxide or cesium fluoride,
- or a nickel catalyst such as nickel on charcoal or  $Ni(dppe)Cl_2$  together with Zn and sodium triphenylphosphine trimetasulfonate. A suitable base such as an alkylamine e.g.
- 15 triethylamine, or potassium carbonate, potassium phosphate, sodium carbonate, sodium hydroxide or cesium fluoride may be used in the reaction, which reactions are performed in a temperature range between +20 °C and +160 °C using an oil bath or a microwave oven in a suitable solvent such as ethanol, water, toluene, tetrahydrofuran, glycol dimethyl ether or *N,N*-dimethylformamide or mixtures thereof.


20

(v) conversion of a compound of formula **VI**, wherein  $R^8$  is  $C_{1-6}$ alkyl, to a compound of formula **VI**, wherein  $R^8$  is hydrogen, may be carried out in a suitable solvent such as tetrahydrofuran or water or mixtures thereof in the presence of a suitable base such as potassium carbonate, sodium hydroxide or lithium hydroxide at a reaction temperature


25 between +20 °C and +60 °C.



(vi) halogenating a compound of formula **VII**, wherein  $R^9$  is halogen e.g. bromine, or  $NH_2$  and  $P$ ,  $R^3$  and  $n$  are as defined above, to obtain a compound of formula **VIII** may be carried out by treatment of a compound of formula **VII** with a halogenation reagents such as thionyl chloride or oxalyl chloride. The reaction may be performed neat or in a suitable solvent such as tetrahydrofuran, dioxane or methylene chloride at a temperature range between  $-20\text{ }^{\circ}\text{C}$  and  $+60\text{ }^{\circ}\text{C}$ ;




(vii) amidation of a compound of formula **VIII**, wherein  $R^9$  is halogen e. g. bromine, or  $NH_2$ , and  $P$ ,  $R^3$  and  $n$  are as defined above, to obtain a compound of formula **IX**, may be carried out by reacting a compound of formula **VIII** with the suitable amine  $HNR^1R^2$ . The reaction may be performed in a suitable solvent such as tetrahydrofuran, dioxane, *N,N*-dimethylformamide or methylene chloride with or without a suitable base such as a trialkylamine e.g. triethylamine, or potassium carbonate, sodium hydroxide or sodium hydrogen carbonate in a temperature range between  $0\text{ }^{\circ}\text{C}$  and  $+50\text{ }^{\circ}\text{C}$ .



(viii) conversion of a compound of formula **X** to obtain a compound of formula **XI**, wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $n$  and  $P$  are as defined above, may be carried out by treatment of a compound of formula **X** with sodium nitrite and hydrobromic acid followed by the




addition of a bromide source such as CuBr in an appropriate solvent such as water at a temperature range between 0 °C and +5 °C.




- (ix) formation of an amide of formula **XIII**, wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $n$  and  $\text{P}$  are as defined above, may be carried out by treating a compound of formula **XII**, wherein  $\text{R}^8$  is  $\text{C}_{1-6}$ alkyl, with the appropriate amine  $\text{HNR}^1\text{R}^2$ . The reaction can be performed neat or using a suitable solvent such as *N,N*-dimethylformamide, methylene chloride or ethyl acetate at a temperature ranging from  $-25\text{ }^{\circ}\text{C}$  to  $+150\text{ }^{\circ}\text{C}$ . The reaction may be aided by using a base such as potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene or an acid such as trimethylaluminum or *p*-toulenesulfonic acid.
- (x) amidation of a compound of formula **XII**, wherein  $\text{R}^8$  is hydrogen and  $\text{R}^3$ ,  $n$  and  $\text{P}$  are as defined above to obtain a compound of formula **XIII** may be performed by activation of a compound of formula **XII** by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate, followed by treatment with the appropriate amine  $\text{HNR}^1\text{R}^2$ . The reaction may be carried out in a suitable solvent such as *N,N*-dimethylformamide, acetonitrile or methylene chloride at a temperature ranging from  $-25\text{ }^{\circ}\text{C}$  to  $+150\text{ }^{\circ}\text{C}$ , with

or without a suitable base such as an alkylamine e.g. triethylamine, *N*-ethyl-*N,N*-diisopropylamine or *N*-methylmorpholine, or potassium carbonate or sodium hydroxide.



(xi) conversion of a compound of formula **XIV**, wherein  $R^3$ ,  $n$  and  $P$  are as defined above, to obtain a compound of formula **XV**, wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $n$  and  $P$  are as defined above, may be carried out by reacting a compound of formula **XIV** with a suitable alcohol,  $R^1R^2\text{NC}_{1-6}\text{alkylOH}$  in the presence of triphenylphosphine and an appropriate azidodicarboxylate such as diethyl azidodicarboxylate. The reaction may be performed in a suitable solvent such as tetrahydrofuran, toluene or methylene chloride and at a reaction temperature between 0 °C to 60 °C.

15






(xii) borylation of compounds of formula **XI**, **XIII** and **XV** to compounds of formula **XVIa-c** (**XVIa** from **XI**, **XVIb** from **XV** and **XVI** from **XIII**), wherein  $P$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $C_{1-6}\text{alkyl}$  and  $n$  are as defined above and  $R^{10}$  may be a group outlined in Scheme I, wherein  $R^{11}$  and  $R^{12}$  are  $C_{1-6}\text{alkoxy}$  or hydroxy, or  $C_{1-3}\text{alkoxy}$  fused together to form a 5 or 6 membered cyclic boron-oxygen- $C_{2-3}\text{alkyl}$  species and the alkoxy, the aryl group or 5 or 6 membered cyclic boron-oxygen- $C_{2-3}\text{alkyl}$  species may be optionally substituted, may be carried out by a reaction with:

25

a) butyllithium or magnesium and a suitable boron compound such as trimethyl borate or triisopropyl borate. The reaction may be performed in a suitable solvent such as tetrahydrofuran, hexane or methylene chloride in a temperature range between  $-78^{\circ}\text{C}$  and  $+20^{\circ}\text{C}$ ;


5 or,

b) a palladium catalyst such as palladium tetrakis(triphenylphosphine), palladium diphenylphosphineferrocene dichloride or palladium acetate with or without a suitable ligand such as 2-(dicyclohexylphosphino)biphenyl, and a suitable boron species such as bis(catecholato)diboron, bis(pinacolato)diboron or pinacolborane. A suitable base, which  
10 under the reaction conditions do not promote dimerisation of compounds of formula **XI**, **XIII** and **XV**, such as a tertiary amine such as triethylamine or diisopropylethylamine or potassium acetate may be used. The reaction may be performed in a solvent such as dioxane, toluene or acetonitrile at temperatures between  $+80^{\circ}\text{C}$  and  $+100^{\circ}\text{C}$ .




**Scheme I.** Examples but not limitations of  $\text{R}^{10}$

15




(xiii) conversion of a compound of formula **XVII**, wherein  $\text{R}^8$  is  $\text{C}_{1-6}$ alkyl and  $\text{R}$ ,  $\text{R}^3$ ,  $\text{P}$ ,  $\text{X}$ ,  
20  $\text{Z}$  and  $m$  are as defined above, to a compound of formula **XVIII**, wherein  $\text{E}$  and  $\text{F}$  are a

methoxy group or hydrogen and G is a spacer chain containing atoms selected from oxygen and carbon, may be carried out by reaction with a suitable solid phase reagent such as a formyl polystyrene e.g. 2-(3,5-dimethoxy-4-formylphenoxy)ethyl polystyrene or 2-(4-formyl-3-methoxyphenoxy)ethyl polystyrene in a suitable solvents such as *N,N*-dimethylformamide or methylene chloride in the presence of a suitable acid e.g. acetic acid and a suitable reducing reagent such as sodium triacetoxyborohydride or sodium cyanoborohydride at a suitable reaction temperature ranging between 0 °C and +50 °C. The reaction may be aided by the presence of trimethylsilyl chloride.



(XIX)


(xiv) hydrolysis of a compound of formula XVIII, wherein R, R<sup>3</sup>, R<sup>8</sup>, P, X, Z, and m are as defined above, and wherein E and F are a methoxy group or hydrogen and G is a spacer chain containing atoms selected from oxygen and carbon, to a compound of formula XIX may be carried out in a suitable solvent such as water, tetrahydrofuran or mixtures thereof in the presence of a suitable base such as sodium hydroxide, potassium hydroxide or lithium hydroxide at a suitable reaction temperature ranging between +25 °C and reflux.




(IX)

(xv) conversion of a compound of formula IX, wherein R<sup>1</sup>, R<sup>3</sup>, P and n are as defined above and R<sup>2</sup> is C<sub>1-6</sub>alkylOR<sup>6</sup> where R<sup>6</sup> is hydrogen and R<sup>9</sup> is halogen e.g. bromine, or

NH<sub>2</sub>, to a compound of formula IX, wherein R<sup>1</sup>, R<sup>3</sup>, R<sup>9</sup>, P and n are as defined above and R<sup>2</sup> is C<sub>1-6</sub>alkylOR<sup>6</sup> and R<sup>6</sup> is C<sub>1-6</sub>alkyl, may be carried out in a suitable solvent such as methylene chloride or chloroform using a suitable reagent such as (trimethylsilyl)diazomethane in a reaction temperature between 0 °C and 20 °C. The reaction may be aided by the use of a reagent such as fluoroboric acid.



(xvi) conversion of a compound of formula IV, wherein Z, X, Q, Y, R<sup>4</sup> and m are as defined above and Hal is halogen, to a compound of formula XX, wherein Z, X, Q, Y, R<sup>4</sup> and m are as defined above, may be carried out by the method described in (iv) using a compound of formula XXI, wherein P, R<sup>3</sup>, R<sup>9</sup> and n are as defined above.




### Methods of preparation of the end products

Another object of the invention are processes for the preparation of a compound of general formula I, wherein Y, X, Z, P, Q, R, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, A, m and n are, unless specified otherwise, defined as in formula I, comprising of:

**A**

De-halogen coupling, wherein  $R^3$  and  $R^4$  are substituents that are not susceptible to certain agents in the reaction, of a compound of formula **IV** with a appropriate aryl species to give a compound of formula **I**:



Thus, the de-halogen coupling according to process **A** may be carried out by coupling of a compound of formula **IV** with:

a) an appropriate aryl halogen such as aryl iodide, aryl bromide or aryl chloride in the presence of metals such as copper, nickel or zinc and nickel complexes, copper oxide or palladium acetate and tetrabutylammonium bromide and a base such as potassium carbonate or triethylamine. The reaction may occur at a temperature between 20 °C and 180 °C in a suitable solvent such as *N,N*-dimethylformamide, toluene or 2-pentanol;

or,

b) an appropriate aryl boronic acid or a boronic ester such as compounds of formula **XVIa-c** (the boronic acid or boronic ester may be formed in situ using the compounds of formula **XI**, **XIII** and **XV** and conditions described in (xii)). The reaction may be carried out using a suitable palladium catalyst such as  $Pd(PPh_3)_4$ ,  $Pd(dppf)Cl_2$  or  $Pd(OAc)_2$  with or without a suitable ligand such as  $P(tert\text{-}butyl)_3$  in the presence of a suitable base such as an alkylamine e.g. triethylamine, or potassium carbonate, sodium carbonate, sodium hydroxide or cesium fluoride, which is performed in a temperature range between +20 °C and +160 °C using an oil bath or a microwave oven in a suitable solvent or solvent mixture

such as toluene, tetrahydrofuran, ethylene glycol dimethyl ether/water, dimethoxyethane/water or *N,N*-dimethylformamide;

or,

2-(dicyclohexylphosphino)biphenyl or a nickel catalyst such as nickel on charcoal or

- 5 Ni(dppe)Cl<sub>2</sub> together with Zn and sodium triphenylphosphinetrimetasulfonate. A suitable base such as an alkylamine e.g. triethylamine, or potassium carbonate, sodium carbonate, sodium hydroxide or cesium fluoride may be used in the reaction, which is performed in the temperature range between +20 °C and +160 °C using an oil bath or in a microwave oven in a suitable solvent or solvent mixture such as toluene, tetrahydrofuran, 10 tetrahydrofuran/water, dimethoxyethane/water or *N,N*-dimethylformamide;

or,


c) an appropriate aryl stannane in the presence of palladium catalyst such as Pd(PPh<sub>3</sub>)<sub>4</sub>, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> or Pd(dba)<sub>3</sub> and if needed a helping reagent such as 4-tert-butylcatechol, lithium chloride or potassium carbonate. Suitable solvents may be toluene, tetrahydrofuran 15 or *N,N*-dimethylformamide. The reaction may occur in a temperature range of +20 °C and +120 °C;

or,

d) an appropriate aryl halogen such as aryl iodide or aryl bromide by treatment with butyllithium in a suitable solvent such as tetrahydrofuran at a reaction temperature between 20 -78 °C and -25 °C, and a suitable base such as sodium carbonate or potassium carbonate in the presence of a suitable palladium catalyst such as Pd(dppf)Cl<sub>2</sub> or Pd(OAc)<sub>2</sub> and at a reaction temperature between 25 °C and reflux.

## B

- 25 Amidation, wherein R<sup>3</sup> and R<sup>4</sup> are substituents that are not susceptible to certain agents in the reaction, of a compound of formula VI with the appropriate amine:




Thus, the amidation according to process B may be carried out by treating a compound of  
 5 formula VI, wherein  $R^8$  is  $C_{1-6}$ alkyl, with the appropriate amine such as a compound of  
 formula V. The reaction can be performed neat or using a suitable solvent such as *N,N*-  
 dimethylformamide, acetonitrile, methylene chloride or ethyl acetate at a temperature  
 ranging from  $-25\text{ }^{\circ}\text{C}$  to  $+150\text{ }^{\circ}\text{C}$ . The reaction may be aided by using a base such as  
 potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene or an acid such  
 10 as trimethylaluminum or *p*-toulenesulfonic acid;  
 or,  
 the amidation of a compound of formula VI, wherein  $R^8$  is hydrogen, may be performed by  
 activation of a compound of formula VI by treating the compound with coupling reagents  
 such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide  
 15 hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N,N,N',N'*-  
 tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-*N,N,N',N'*-  
 tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-  
 azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate where the  
 reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl  
 20 halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or  
 bromotrispyrrolidinophosphonium hexafluorophosphate followed by treatment with the  
 appropriate amine such as a compound of formula V in a suitable solvent such as  
 methylene chloride chloroform, *N,N*-dimethylformamide, acetonitrile, tetrahydrofuran or  
 mixtures thereof and at a reaction temperature between  $0\text{ }^{\circ}\text{C}$  and reflux. The reaction may be  
 25 aided by using a base such as potassium carbonate or a trialkylamine e.g triethylamine or  
*N*-ethyl-*N,N*-diisopropylamine



## C

Amidation, wherein  $R^3$  and  $R^4$  are substituents that are not susceptible to certain agents in the reaction, of a compound of formula XX, with the appropriate amine to give a compound of formula I:


5



- 10 Thus the amidation of a compound of formula XX according to process C may be performed by activation of the carboxylic acid function in a compound of formula XX, by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium
- 15 tetrafluoroborate, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium
- 20 hexafluorophosphate in a suitable solvent such as *N, N*-dimethylformamide, methylene chloride, methanol, dioxane or tetrahydrofuran followed by treatment with the appropriate amine  $HNR^1R^2$  and at a reaction temperature between 25 °C and 70 °C.

**D**

Amidation, wherein  $R^3$  and  $R^4$  are substituents that are not susceptible to certain agents in the reaction, of a compound of formula XIX with the appropriate amine:



- 10 Thus, the amidation of a compound of formula XIX, may be performed by activation of a compound of formula XIX by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium
- 15 hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate followed by treatment with the appropriate amine such as a
- 20 compound of formula V in a suitable solvent such as methylene chloride chloroform, *N, N*-dimethylformamide, acetonitrile or tetrahydrofuran and at a reaction temperature between 0 °C and reflux. The reaction may be aided by using a base such as potassium carbonate or a trialkylamine e.g triethylamine or *N*-ethyl-*N, N*-diisopropylamine, followed by,
- 25 cleavage of the solid phase moiety by treatment with an suitable acid such as trifluoroacetic acid in a suitable solvent such as methylene chloride or chloroform and at a reaction temperature between 0 °C and reflux to give the compound of formula (I).

The hydrochloric salt of compound of formula I may be obtained from a compound of formula I by treatment with hydrochloric acid at a temperature range between 0 °C and +25 °C, in suitable solvent such as methylene chloride, tetrahydrofuran or methylene chloride/methanol mixture.

## WORKING EXAMPLES

### Example 1

#### 10 3-Amino-6-bromo-N-pyridin-3-ylpyrazine-2-carboxamide

To 3-aminopyridine (10 g, 106 mmol) at 70 °C were added methyl 3-amino-6-bromo-2-pyrazinecarboxylate (1.0 g, 4.3 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (645 µL, 4.3 mmol). The reaction solution was stirred for 4 h, diluted with water (75 mL) and extracted with methylene chloride. The combined organic layers were washed with a saturated ammonium chloride solution, dried (MgSO<sub>4</sub>), filtered and evaporated in vacuo. The crude product was purified on a silica gel column using methylene chloride/ethanol, (9:1), as the eluent to give 750 mg (59% yield) of the title compound as a yellow solid: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 9.50 (br s, 1 H), 8.82 (d, *J* = 3 Hz, 1 H), 8.43 (dd, *J* = 5 and 1 Hz, 1 H), 8.31 (s, 1 H), 8.23 (ddd, *J* = 8, 3 and 2 Hz, 1 H), 7.34 (dd, *J* = 8, 5 Hz, 1 H); MS (TSP) *m/z* 294 (M<sup>+</sup>+1).

### Example 2

#### 1-[(4-Bromophenyl)sulfonyl]pyrrolidine

Pyrrolidine (2.5 g, 35.2 mmol) was added to a solution of 4-bromobenzenesulfonyl chloride (4.5 g, 17.6 mmol) in methylene chloride (10 mL) at 0 °C. The mixture was stirred for 2 h and an aqueous sodium hydroxide solution (1 M, 5 mL) was added and stirring was continued for another 10 min. The organic phase was separated and diluted with methylene chloride (40 mL), washed with aqueous HCl (1 M, 10 mL), and water (2x10 mL). The organic phase was dried (sodium sulfate) and the solvent was evaporated. The title compound was isolated in 5.0 g (98% yield) as a white solid: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.65 (m, 4 H), 3.20 (m, 4 H), 1.74 (m, 4 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 135.93, 132.17, 128.84, 127.39, 47.84, 25.13; MS (ES) *m/z* 290 and 292 (M<sup>+</sup>+1).

**Example 3****4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid**

*n*-Butyllithium (20 mL, 31 mmol) was added dropwise over 30 min to a cooled (-78 °C) solution of 1-[(4-bromophenyl)sulfonyl]pyrrolidine (3.0 g, 10.3 mmol) and triisopropyl borate (7.2 mL, 30.9 mol) in anhydrous tetrahydrofuran (10 mL) under a nitrogen atmosphere. The reaction mixture was stirred for 1 h at -78 °C whereafter the temperature was allowed to reach room temperature over 3 h. Silica gel was added and the solvent was evaporated. Chromatography on a silica gel column using a gradient methylene chloride (100%) to methylene chloride/ethanol, (1:1), gave 1.85 g (70% yield) of the title compound as a white solid: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 7.90 (d, *J* = 7 Hz, 2 H), 7.75 (d, *J* = 8 Hz, 2 H), 3.21 (m, 4 H), 1.72 (m, 4 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>/CD<sub>3</sub>OD (1:1), 100 MHz) δ 136.79, 133.50, 125.48, 47.19, 24.30; MS (ES) *m/z* 256 (*M*<sup>+</sup>+1).

**Example 4****4-Bromo-*N*-[(1*R*)-2-hydroxy-1-methylethyl]benzenesulfonamide**

(2*R*)-2-Aminopropan-1-ol (2.0 g, 26.7 mmol) and *N*-ethyl-*N,N*-diisopropylamine (8.5 mL, 48.9 mmol) was added dropwise over 20 min to a cooled (0 °C) solution of 4-bromobenzenesulfonyl chloride (6.12 g, 24 mmol) in methylene chloride (20 mL). The reaction mixture was allowed to stir for 1 h. Water was added and the mixture was washed, twice, with HCl (aq, 1 M) and one time with saturated aqueous sodium hydrogen carbonate. The organic phase was dried over sodium sulfate and evaporated to give 6.8 g, (96% yield) of the title compound: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 7.82 (d, *J* = 8 Hz, 2 H), 7.76 (d, *J* = 8 Hz, 2 H), 3.44 (m, 1 H), 3.34 (m, 3 H), 1.03 (d, *J* = 7 Hz, 3 H); MS (ESI) *m/z* (*M*<sup>+</sup>+1); <sup>13</sup>C NMR (CD<sub>3</sub>OD, 100 MHz) 142.42, 133.36, 129.74, 127.90, 66.81, 52.49, 17.94

**Example 5****4-Bromo-*N*-[(1*R*)-2-methoxy-1-methylethyl]benzenesulfonamide**

(Trimethylsilyl)diazomethane (10 mL, 10 mmol) was added to a vigorously stirred mixture of 4-bromo-*N*-[(1*R*)-2-hydroxy-1-methylethyl]benzenesulfonamide (1.0 g, 3.4 mmol) and aqueous fluoroboric acid (conc. 42%, 6.8 mmol) in methylene chloride (25 mL), in 5

portions over 1 h at 0 °C. The stirring was continued at 0 °C and another portion of trimethylsilyldiazomethane (5 mL, 5 mmol) was added over 30 min. The stirring was continued for 30 min, poured into water and extracted with methylene chloride. The organic phase was washed with water, dried over sodium sulfate and concentrated.

- 5 Purification by column chromatography using gradient heptane to heptane/ethylacetate, (2:1), as the eluent gave 0.155 g (15% yield) of the title compound: MS (ESI) 309  $m/z$  ( $M^+ + 1$ ).

### Example 6

10 **4-Bromo-*N*-[(1*S*)-2-methoxy-1-methylethyl]benzenesulfonamide**

- (1*S*)-2-Methoxy-1-methylethylamine (7.34 g, 82.4 mmol) and *N*-ethyl-*N,N*-diisopropylamine (19.1, 110 mmol) was added dropwise over 20 min to a cooled (0 °C) solution of 4-bromobenzenesulfonyl chloride (14.0 g, 55 mmol) in methylene chloride (200 mL). The reaction mixture was allowed to stir for 1 h. Water was added and the  
15 mixture was washed, twice, with HCl (1 M) and once with saturated aqueous sodium hydrogen carbonate. The organic phase was dried over sodium sulfate and evaporated to give 15.1 g, (94% yield) of the title compound:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  7.76 (d,  $J$  = 8 Hz, 2 H), 7.65 (d,  $J$  = 8 Hz, 2 H), 4.97 (m, 1 H), 3.46 (m, 1 H), 3.23 (m, 5 H), 1.12 (d,  $J$  = 7 Hz, 3 H); MS (ESI)  $m/z$  308 and 310 ( $M^+ + 1$ )

20

### Example 7

**Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate**

- 4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid (0.33 g, 1.29 mmol), methyl 3-amino-6-bromopyrazine-2-carboxylate (0.25 g, 1.08 mmol; described in: H. Ellingson, *J. Amer. Chem. Soc.* **1949**, 2798),  $\text{K}_3\text{PO}_3$  (3 M, 1.1 mL, 3.2 mmol), and  $\text{Pd}(\text{dppf})\text{Cl}_2$  (0.044 g, 54  $\mu\text{mol}$ ) were suspended in ethylene glycol dimethyl ether/water (1.5:0.5 mL) and heated in a microwave oven at 160 °C for 10 min. The reaction was repeated 3 times. The combined product mixtures were evaporated with silica gel and the crude product was purified by chromatography on silica gel using a heptane to ethyl acetate gradient to give 0.96 g (82%  
25 yield) of the title compound: MS (ES)  $m/z$  363 ( $M^+ + 1$ ).
- 30

**Example 8****4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid**

Triisopropyl borate (0.64 mL, 2.8 mmol) was added to a solution of 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine (0.602 g, 1.9 mmol; described: in Keasling, H. H. et al. *J. Med. Chem.* **1965**, 8, 548-550) in anhydrous tetrahydrofuran (7 mL) at -78 °C under a nitrogen atmosphere followed by dropwise addition of *n*-butyllithium (1.4 mL, 2.2 mmol). The resulting mixture was stirred at -78 °C for 2 h and at room temperature for another 16 h. Water (2.0 mL) was added and the mixture stirred for 30 min and evaporated to dryness. The residue was pre-adsorbed onto silica and purified by column chromatography using methylene chloride/methanol, (9:1 to 1:9), as the eluent. The product was re-crystallized from water to give 311 mg (58% yield) of the title compound as white crystals: mp 215-218 °C; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz) δ 10.89 (br s, 1 H), 8.47 (br s, 2 H), 8.05 (d, *J* = 8 Hz, 2 H), 7.73 (d, *J* = 8 Hz, 2 H), 3.77 (m, 2 H), 3.40 (m, 2 H), 3.13 (m, 2 H), 2.71 (s, 3 H), 2.65 (m, 2 H); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>, 100 MHz) δ 133.7, 133.3, 124.7, 49.8, 41.6, 41.4; MS (TSP) *m/z* 285 (M<sup>+</sup>+1).

**Example 9****Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate**

Triisopropyl borate (2.7 mL, 11.6 mmol) was added to a solution of 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine in (1.24 g, 3.87 mmol; described: in Keasling, H. H. et al. *J. Med. Chem.* **1965**, 8, 548-550) in anhydrous tetrahydrofuran (25 mL) at -78 °C under an atmosphere of nitrogen, followed by dropwise addition of *n*-butyllithium (9.8 mL, 15.5 mmol). The resulting mixture was stirred at -78 °C for 30 min, then allowed to warm to room temperature. HCl (3 M aq, 7.8 mL, 23.2 mmol) was added and the mixture was stirred at room temperature for 10 min. Sodium carbonate (4.1 g, 38.7 mmol) was added followed by the addition of methyl 3-amino-6-bromo-2-pyrazinecarboxylate (0.79 g, 3.4 mmol; described in: H. Ellingson, *J. Amer. Chem. Soc.* **1949**, 2798) and Pd(dppf)Cl<sub>2</sub> (95 mg, 0.12 mmol). The resulting mixture was heated at 55 °C overnight. Silica was added, the solvent was evaporated and the crude mixture was purified by column chromatography on silica using chloroform/methanol, (99:1), as the eluent to give 0.923 g

(69% yield) of the base as a yellow solid:  $^1\text{H}$ NMR (DMSO- $d_6$ )  $\delta$  9.0 (s, 1 H), 8.22 (d,  $J$  = 7 Hz, 2 H), 7.80 (d,  $J$  = 7 Hz, 2 H), 7.62 (br s, 2 H), 3.90 (s, 3 H) 2.91 (m, 4 H), 2.36 (m, 4 H), 2.12 (s, 3 H);  $^{13}\text{C}$ NMR (DMSO- $d_6$ )  $\delta$  166.2, 155.1, 145.8, 140.33, 127.5, 134.0, 128.1, 125.7, 109.1, 53.5, 52.3, 45.7, 45.2; MS (ESP)  $m/z$  392 ( $M^+$ +1).

5

### Example 10

#### 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid

Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate was dissolved in anhydrous tetrahydrofuran (10 mL). Lithium hydroxide (0.113 g, 4.72 mmol) in water (19 mL) was added at room temperature and the resulting mixture was stirred at 50 °C for 3 h. The tetrahydrofuran was evaporated and the pH of the water phase was adjusted to 6 with HCl (aq). The precipitated product was filtered and washed with water and dried to give 0.763 g (86% yield) of the title compound as a pale yellow solid:  $^1\text{H}$ NMR (TFA)  $\delta$  8.83 (s, 2 H), 8.23 (m, 2 H), 7.97 (m, 2 H), 4.09 (m, 2 H), 3.76 (m, 2 H), 2.25 (m, 2 H), 3.04 (m, 5 H);  $^{13}\text{C}$ NMR (TFA)  $\delta$  165.81, 147.39, 139.5, 139.2, 135.7, 132.1, 131.1, 128.5, 127.3, 53.9, 43.5, 43.2; MS (ESP)  $m/z$  378 ( $M^+$ +1).

15

### Example 11

#### 4-[2-(4-Bromo-2-fluorophenoxy)ethyl]morpholine

A mixture of 4-bromo-2-fluorophenol (0.612 g, 3.2 mmol; described: in Finger et al. *J. Amer. Chem. Soc.* **1959**, *81*, 94), 4-(2-hydroxyethyl)morpholine (0.47 ml, 3.84 mmol) and triphenylphosphine (1.0 g, 3.84 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL) and cooled to 0 °C. Diethyl azodicarboxylate (0.6 mL, 3.84 mmol) was added dropwise and the resulting mixture was stirred at room temperature for 3.5 h. The solvent was evaporated and the residue partitioned between water and methylene chloride. The organic phase was washed twice with a saturated sodium hydrogen carbonate solution, dried ( $\text{MgSO}_4$ ) and the solvent was evaporated. The product was purified by column chromatography on silica using a gradient of toluene/acetonitrile, (4:1 to 0:1), as the eluent to give 0.655 g (67% yield) of the title compound as a clear oil:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  7.21 (d,  $J$  = 11 Hz, 1 H), 7.16 (m, 1 H), 6.83 (t,  $J$  = 9 Hz, 1 H), 4.14 (t,  $J$  = 6 Hz, 2 H), 3.71 (t,  $J$  = 5 Hz, 4 H), 2.80 (t,  $J$  = 6 Hz, 2 H), (t,  $J$  = 5 Hz, 4 H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100)  $\delta$  154.2,

30

151.7, 146.5, 146.4, 127.4, 127.4, 120.1, 119.9, 116.8, 116.8, 112.7, 112.7, 68.1, 67.1, 57.6, 54.3; MS (ESP)  $m/z$  304, 306 ( $M^+ + 1$ ).

### Example 12

#### 5 **4-Bromo-*N*-(1-ethyl-3-piperidiny)benzenesulfonamide**

3-Amino-1-ethylpiperidine (0.4 mL, 3.13 mmol) was added to a solution of 4-bromobenzenesulfonyl chloride (0.4 g, 1.56 mmol) in methylene chloride (10 mL) at room temperature. The mixture was stirred overnight. The reaction solution was extracted three times with a aqueous saturated sodium hydrogen carbonate solution, dried ( $MgSO_4$ ) and  
10 evaporated to give 0.533 g (93% yield) of the title compound as a light brown solid:  $^1H$  NMR ( $CDCl_3$ )  $\delta$  7.74 (d,  $J = 9$  Hz, 2 H), 7.62 (d,  $J = 9$  Hz, 2 H), 3.45 (br s, 1 H), 2.46 (br s, 1 H), 2.27 (m, 2 H), 2.23 (m, 2 H), 2.13 (m, 1 H), 1.64 (m, 1 H), 1.45 (m, 3 H), 0.93 (t,  $J = 7$  Hz, 3 H);  $^{13}C$  NMR ( $CDCl_3$ )  $\delta$  140.7, 132.5, 128.7, 127.5, 53.2, 52.3, 49.7, 21.9, 12.1; MS (ESP)  $m/z$  347, 349 ( $M^+ + 1$ ).

15

The following Examples, 13-14, were synthesized as described for Example 12:

### Example 13

#### **4-Bromo-*N,N*-bis(2-methoxyethyl)benzenesulfonamide**

20 Starting materials: bis(2-methoxyethyl)amine and 4-bromobenzenesulfonyl chloride.

Yield: 99% as a yellow oil:  $^1H$  NMR ( $CDCl_3$ )  $\delta$  7.69 (d,  $J = 9$  Hz, 2 H),  $\delta$  7.62 (d,  $J = 9$  Hz, 2 H), 3.49 (m, 4 H), 3.39 (m, 4 H), 3.27 (s, 6 H); MS (ESP)  $m/z$  352, 354 ( $M^+ + 1$ ).

### Example 14

#### 25 **4-bromo-*N*-(3-methylbutyl)-benzenesulfonamide**

Starting materials: isoamylamine and 4-bromobenzenesulfonyl chloride. Yield 98% as a white solid:  $^1H$  NMR ( $CDCl_3$ )  $\delta$  7.71 (d,  $J = 9$  Hz, 2 H), 7.62 (d,  $J = 9$  Hz, 2 H), 4.26 (br s, 1 H), 2.82 (t,  $J = 7$  Hz, 2 H), 1.52 (m, 1 H), 1.30 (q,  $J = 7$  Hz, 2 H), 0.86 (s, 3 H), 0.84 (s, 3 H);  $^{13}C$  NMR ( $CDCl_3$ )  $\delta$  139.3, 132.6, 128.8, 127.7, 41.7, 38.6, 25.6, 22.8, 22.4; MS (ESP)  
30  $m/z$  306, 308 ( $M^+ + 1$ ).



**Example 15****Methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene**

Sodium triacetoxyborohydride (2.6 g, 12.2 mmol) in *N,N*-dimethylformamide/acetic acid (98:2, 20 mL) and trimethylsilyl chloride (1.17 mL, 9.18 mmol) were added to a mixture of methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate (4.4 g, 12.2 mmol) and 2-(3,5-dimethoxy-4-formylphenoxy) ethyl polystyrene (12 g, 0.51 mmol/g) in *N,N*-dimethylformamide (60 mL). The mixture was shaken for 3 h and then filtered. The polystyrene resin was washed, three times, with *N,N*-dimethylformamide and three times with methylene chloride. The procedure was repeated using sodium triacetoxyborohydride (2.6 g, 12.24 mmol) in *N,N*-dimethylformamide/acetic acid, (98:2, 20 mL), trimethylsilyl chloride (1.17 mL, 9.18 mmol) and methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate (12 g, 0.51 mmol/g) and shaking was continued for 18 h. The polystyrene resin was washed, three times, with *N,N*-dimethylformamide, three times with dichloromethane and three times with methanol. The resin was dried under vacuum and gave 12.5 g of the title compound.

Analysis: The title compound (50 mg) was treated with trifluoroacetic acid in dichloromethane (conc. 95%) for 30 min, filtered and the solvent was analyzed by MS: MS (ESI) 363 *m/z* ( $M^+ + 1$ ) (which corresponds to the starting material).

**Example 16****3-{[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene**

A solution of lithium hydroxide (4 M, 10 mL) was added to a suspension of methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene (12 g, 0.51 mmol/g) in tetrahydrofuran (100 mL). The mixture was shaken for 17 h. Filtering and washing of the resin three times with *N,N*-dimethylformamide/water, (4:1), and three times with *N,N*-dimethylformamide/acetic acid, (98:2,) and three times with methanol and drying of the resin gave 11.8 g of the title compound.

Analysis: The title compound (50 mg) was treated with trifluoroacetic acid in dichloromethane (conc. 95%) for 30 min, filtered and the solvent was analyzed by MS: MS (ESI) 349  $m/z$  ( $M^+ + 1$ ).

5 **Example 17**

**3-Amino-6-[4-(((1*R*)-2-methoxy-1-methylethyl)amino)sulfonyl]phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride.**

*n*-Butyllithium (1.3 mL, 2.1 mmol) was added dropwise over 30 min to a cooled (-78 °C) solution of 4-bromo-*N*-[(1*R*)-2-methoxy-1-methylethyl]benzenesulfonamide (0.125 g, 0.406 mmol) and triisopropyl borate (0.28 mL, 1.2 mmol) in anhydrous tetrahydrofuran (10 mL) under nitrogen atmosphere. The reaction mixture was stirred for 2 h at -78 °C. HCl (aq, 3 M, 0.81 mL) was added to the reaction mixture and the mixture was allowed to warm to room temperature. Sodium carbonate (0.516 g, 4.9 mmol) was added followed by Pd(dppf)Cl<sub>2</sub> (16 mg, 20 μmol) and 3-amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-  
15 carboxamide (0.143 g, 0.487 mmol). Tetrahydrofuran (10 mL) was added and the mixture was heated to 65 °C for 15 h. The solvent was removed and purification by column chromatography using gradient methylene chloride to methylene chloride/methanol, (2:1), as the eluent gave a yellow solid. The solid was dissolved in methylene chloride (10 mL) and HCl in diethyl ether (1 M 2.5 ml) was added. A yellow precipitate was formed.  
20 Filtering and drying gave 73 mg (35% yield) of the title compound as yellow solid: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 9.28 (s, 1 H), 8.53 (s, 3 H), 8.0 (m, 1 H), 7.96 (d, *J* = 8 Hz, 2 H), 7.70 (d, *J* = 8 Hz, 2 H), 3.42 (m, 1 H), 3.27 (m, 1 H), 3.16 (s, 3 H), 0.93 (d, *J* = 7 Hz, 3 H);

**Example 18**

25 **3-Amino-6-[4-(((1*S*)-2-methoxy-1-methylethyl)amino)sulfonyl]phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride**

The title compound was prepared as described for Example 17 using 4-bromo-*N*-[(1*S*)-2-methoxy-1-methylethyl]benzenesulfonamide. Yield: 77 % of the title compound as yellow solid: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 9.27 (s, 1 H), 8.53 (m, 3 H), 8.0 (d, *J* = 8 Hz, 2 H), 7.99 (m, 1 H), 7.70 (d, *J* = 8 Hz, 2 H), 3.42 (m, 1 H), 3.26 (d, m, 2 H), 3.25 (s, 3 H), 0.92 (d, *J* = 6 Hz, 3 H); MS (ESI) 443  $m/z$  ( $M^+ + 1$ ).

**Example 19****3-Amino-*N*-(3-nitrophenyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide**

3-Nitroaniline (70 mg, 0.51 mmol), O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium tetrafluoroborate (0.164 g, 0.51 mmol) and 1-hydroxybenzotriazole hydrate (69 mg, 0.51 mmol) were added to 3- $\{[2,6\text{-dimethoxy-4-(2-phenylethoxy)benzyl}]amino\}$ -6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene (0.50 g, 0.51 mmol/g, 0.255 mmol) in *N,N*-dimethylformamide (2 mL). The mixture was shaken for 5 min where after *N*-ethyl-*N,N*-diisopropylamine (0.133 mL, 0.765 mmol) was added. The mixture was shaken for 18 h, filtered and washed *N,N*-dimethylformamide and three times with methylene chloride. The product was isolated by treating the resin with trifluoroacetic acid in methylene chloride (conc. 95%) for 30 min and then filtered. The solution was evaporated and purification by preparative HPLC (column: XTerra C8 19x300 mm, eluent: gradient acetonitrile/water, (20:80 to 80:20)), gave 3.1 mg (1.3% yield) of the title compound:  $^1\text{H NMR}$  ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  8.60 (s, 1 H), 7.99 (m, 3 H), 7.80 (m, 3 H), 7.50 (d,  $J = 8$  Hz, 2 H), 7.38 (t,  $J = 8$  Hz, 1 H), 3.15 (m, 4 H), 1.68 (m, 4 H); MS (ESI) 439  $m/z$  ( $M^+ + 1$ ).

**Example 20****3-Amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-*N*-1*H*-tetrazol-5-ylpyrazine-2-carboxamide.**

The title compound was prepared as described Example 19 using 1*H*-tetrazol-5-amine. Yield: 1.1%; MS (ESI) 416  $m/z$  ( $M^+ + 1$ ).

**Example 21****3-Amino-*N*-(2-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

2-Methoxyaniline (80 mg, 318 mmol) was added to a mixture of 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid (80 mg, 212 mmol), O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium tetrafluoroborate (82 mg, 255 mmol), 1-hydroxybenzotriazole hydrate (34 mg, 255 mmol) and *N*-ethyl-*N,N*-diisopropylamine (0.111 mL, 0.637 mmol) in *N,N*-dimethylformamide (2 mL). The reaction mixture was

stirred for 13 h. The reaction was quenched with water (1 mL) and the solvent was evaporated. Purification by preparative HPLC (column: XTerra C8 19x300 mm, eluent: a acetonitrile/water, (20:80 to 80:20), gradient) followed by evaporation of the solvent gave a yellowish solid that was dissolved in methylene chloride (10 mL). HCl in diethyl ether (1 M, 2,5 mL) was added while stirring. Filtration and drying gave 12 mg (12% yield) of the title compound: MS (ESI) 483  $m/z$  ( $M^+ + 1$ ).

The following Examples, 22 – 30, were synthesized as described for Example 21:

10 **Example 22**

**3-Amino-*N*-(4-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

Starting material: 4-methoxyaniline. Yield: 62%: MS (ESI) 483  $m/z$  ( $M^+ + 1$ ).

15 **Example 23**

**3-Amino-*N*-[2-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

Starting material: 2-aminobenzamide. Yield: 19%: MS (ESI) 496  $m/z$  ( $M^+ + 1$ ).

20 **Example 24**

**3-Amino-*N*-[3-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

Starting material: 3-aminobenzamide. Yield: 49%: MS (ESI) 496  $m/z$  ( $M^+ + 1$ ).

25 **Example 25**

**3-Amino-*N*-(3-cyanophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

Starting material: 3-aminobenzonitrile. Yield: 19%: MS (ESI) 478  $m/z$  ( $M^+ + 1$ ).

30 **Example 26**

**3-Amino-*N*-(2-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

Starting material: 2-bromoaniline. Yield: 20%: MS (ESI) 531, 533  $m/z$  ( $M^+ + 1$ ).

#### Example 27

**3-Amino-*N*-(3-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

Starting material: 3-bromoaniline. Yield: 2.3%: MS (ESI) 531, 533  $m/z$  ( $M^+ + 1$ ).

#### Example 28

**3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-1*H*-pyrazol-3-ylpyrazine-2-carboxamide hydrochloride**

Starting material: 1*H*-pyrazol-3-amine. Yield: 36%: MS (ESI) 443  $m/z$  ( $M^+ + 1$ ).

#### Example 29

**3-Amino-*N*-[4-(aminocarbonyl)-1*H*-pyrazol-3-yl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

Starting material: 3-amino-1*H*-pyrazole-4-carboxamide. Yield: 36%: MS (ESI) 486  $m/z$  ( $M^+ + 1$ ).

#### Example 30

**3-Amino-*N*-1*H*-imidazol-2-yl-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

Starting material: 1*H*-imidazol-2-amine. Yield: 5%: MS (ESI) 443  $m/z$  ( $M^+ + 1$ ).

#### Example 31

**3-Amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride**

Triisopropyl borate (0.91 mL, 3.96 mmol) was added to a solution of 4-[2-(4-bromo-2-fluorophenoxy)ethyl]morpholine (0.402 g, 1.32 mmol) in anhydrous tetrahydrofuran (10 mL) at  $-78^\circ\text{C}$  under an atmosphere of nitrogen, followed by dropwise addition of *n*-butyllithium (2.5 mL, 3.96 mmol) over 5 min. The resulting mixture was stirred at  $-78^\circ\text{C}$  for 50 min then allowed to warm to room temperature. HCl (3 M aq, 2.2 mL, 6.61 mmol) was added and the mixture was stirred at room temperature for 10 min. Sodium carbonate

(1.40 g, 13.2 mmol) was added followed by the addition of 3-amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-carboxamide (0.272 g, 0.92 mmol) and Pd(dppf)Cl<sub>2</sub> (32 mg, 0.04 mmol). The resulting mixture was heated at 55 °C overnight. Silica was added, the solvent was evaporated and the crude mixture was purified by column chromatography using ethyl acetate as the eluent, followed by chloroform, then using chloroform/methanol, (98:2), to give 0.335 g (58% yield) of the base as a yellow solid: <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>) δ 165.4, 154.4, 163.6, 151.2, 146.8, 146.7, 145.3, 144.8, 143.6, 137.8, 134.9, 129.4, 129.4, 129.0, 123.7, 123.4, 122.1, 115.2, 113.9, 113.7, 79.4, 67.0, 6.5, 57.2, 53.9.

Hydrochloric acid in diethyl ether (0.28 mL, 1 M) was added to a solution of the base (0.324 g, 0.74 mmol) in methylene chloride/methanol, (9:1). The yellow precipitate was filtered off, washed with ethyl acetate, and then purified by preparative HPLC (column: XTerra C8 19x300 mm, eluent: a water/acetonitrile/ammonium acetate gradient). The acetonitrile in the fractions that contained the purified product were evaporated, an aqueous saturated sodium hydrogencarbonate solution was added and extracted, twice, with methylene chloride. The organic phase was dried (MgSO<sub>4</sub>) and the solvent was evaporated giving the base again. Hydrochloride acid in diethyl ether (0.56 mL, 1 M) was added to a solution of the base (0.123 g, 0.28 mmol) in methylene chloride/methanol, (9:1). The yellow precipitate was filtered off, washed with diethyl ether and dried in vacuo to give 120 mg (90% yield) of the title compound as a yellow solid: <sup>1</sup>H NMR (D<sub>2</sub>O) δ 9.37 (d, *J* = 2 Hz, 1 H), 8.62 (m, 1 H), 8.57 (d, *J* = 6 Hz, 1 H), 8.55 (s, 1 H), 8.04 (dd, *J* = 8 and 6 Hz, 1 H), 7.74 (dd, *J* = 13 and 2 Hz, 1 H), 7.64 (m, 1 H), 7.15 (t, *J* = 9 Hz, 1 H), 4.49 (t, *J* = 5 Hz, 2 H), 4.14 (br s, 2 H), 3.91 (br s, 2 H), 3.73 (t, *J* = 5 Hz, 2 H), 3.66 (br s, 2 H), 3.39 (br s, 2 H); MS (ESP) *m/z* 440 (M<sup>+</sup>+1).

The following Examples, 32-34, were synthesized as described for Example 31:

### Example 32

#### 3-Amino-6-[4-[(1-ethyl-3-piperidiny)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride

Starting material: 4-bromo-*N*-(1-ethyl-3-piperidiny)benzenesulfonamide. The crude product was purified on silica using chloroform/methanol, (95:5), as the eluent. Yield 39% of the base.

Hydrochloride, yield: 71%:  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  9.38 (s, 1 H), 8.70 (s, 1 H), 8.63 (d,  $J = 9$  Hz, 1 H), 8.59 (d,  $J = 9$  Hz, 1 H), 8.13 (d,  $J = 8$  Hz, 2 H), 8.06 (dd,  $J = 8$  and 6 Hz, 1 H), 7.86 (d,  $J = 8$  Hz, 2 H), 3.55 (m, 1 H), 3.45 (m, 2 H), 3.45 (m, 2 H), 3.12 (m, 2 H), 2.73 (m, 1 H), 1.54 (m, 4 H), 1.31 (t,  $J = 7$  Hz, 1 H), 8.63 (d,  $J = 7$  Hz, 2 H), 1.16 (t,  $J = 7$  Hz, 1 H);  
5  $^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  165.3, 154.1, 145.5, 140.0, 139.0, 137.6, 137.0, 132.9, 128.0, 127.6, 66.4, 55.3, 52.4, 48.3, 28.4, 21.7, 14.5; MS (TSP)  $m/z$  482 ( $\text{M}^+ + 1$ ).

### Example 33

#### 3-Amino-6-[4-[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride

Starting material: 4-bromo-*N,N*-bis(2-methoxyethyl)benzenesulfonamide. The crude product was purified on silica using heptane/ethylacetate, (1:1), as eluent. Yield: 62% of the base.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  9.79 (s, 1 H), 8.82 (s, 1 H), 8.73 (s, 1 H), 8.41 (d,  $J = 8$  Hz, 1 H), 8.25 (m, 1 H), 8.03 (d,  $J = 8$  Hz, 2 H), 7.99 (d,  $J = 8$  Hz, 2 H), 7.33 (m, 1 H), 3.54 (t,  $J = 6$  Hz, 4 H), 3.41 (t,  $J = 6$  Hz, 4 H), 3.25 (s, 6 H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  164.4, 154.8,  
15 146.0, 145.7, 141.8, 140.1, 139.9, 138.8, 134.2, 128.2, 127.3, 126.2, 124.6, 124.0, 71.7, 59.0, 48.9.

Hydrochloride, yield 78%:  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  9.38 (s, 1 H), 9.05 (s, 1 H), 8.88 (d,  $J = 8$  Hz, 1 H), 8.65 (d,  $J = 5$  Hz, 1 H), 8.42 (d,  $J = 8$  Hz, 2 H), 8.03 (m, 1 H), 7.87 (d,  $J = 8$  Hz, 2 H),  $\delta$  3.41 (t,  $J = 6$  Hz, 4 H), 3.30 (t,  $J = 6$  Hz, 4 H), 3.18 (s, 6 H); MS (ESP)  $m/z$  487 ( $\text{M}^+ + 1$ ).

### Example 34

#### 3-Amino-6-[4-[[[3-methylbutyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride

Starting material: 4-bromo-*N*-(3-methylbutyl)benzenesulfonamide. The crude product was purified on silica using heptane/ethylacetate, (2:1 to 1:2), as eluent. Yield: 62% of the base:  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  9.03 (s, 1 H), 8.99 (d,  $J = 2$  Hz, 1 H), 8.42 (d,  $J = 8$  Hz, 2 H), 8.33 (m, 1 H), 8.18 (m, 1 H), 7.87 (d,  $J = 8$  Hz, 2 H), 7.83 (br s, 2 H), 7.61 (m, 1 H), 7.39 (dd,  $J = 8$  and 5 Hz, 1 H), 2.69 (q,  $J = 7$  Hz, 2 H), 1.50 (sept,  $J = 7$  Hz, 1 H), 1.20 (q,  $J = 7$  Hz, 2 H), 0.80 (s, 3 H), 0.78 (s, 3 H).

Hydrochloride, yield 78%:  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  9.38 (d,  $J = 2$  Hz, 1 H), 9.05 (s, 1 H), 8.91 (d,  $J = 9$  Hz, 1 H), 8.69 (d,  $J = 5$  Hz, 1 H), 8.45 (d,  $J = 8$  Hz, 2 H), 8.06 (dd,  $J = 9$  and 6 Hz, 1 H), 7.84 (d,  $J = 8$  Hz, 2 H), 7.62 (br s, 1 H), 2.71 (br s, 2 H), 1.50 (sept,  $J = 7$  Hz, 1 H), 1.23 (quart,  $J = 7$  Hz, 2 H), 0.80 (s, 3 H), 0.78 (s, 3 H); MS (ESP)  $m/z$  442 ( $\text{M}^+ + 1$ ).

5

### Example 35

#### 3-Amino-6-[4-[[[(1S)-2-methoxy-1-methylethyl]amino]carbonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide hydrochloride

Triethylamine (0.12 mL, 0.89 mmol) was added to a mixture of 4-{5-amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid (100 mg, 0.30 mmol), O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (0.105 g, 0.33 mmol) and 1-hydroxybenzotriazole (44 mg, 0.33 mmol) in methylene chloride/methanol (9:1, 10 mL) at room temperature. (*S*)-(+)-1-methoxy-2-propylamine was added dropwise and the resulting mixture was stirred at room temperature for 1.5 h. The mixture was evaporated onto silica and purified by chromatography on silica using toluene/acetonitrile, (2:1 to 0:1) as the eluent. The formed yellow solid was dissolved in methylene chloride. Hydrochloride acid in diethyl ether (0.4 mL, 1 M) was added and the mixture was stirred at room temperature. The precipitated product was filtrated off and dried in vacuo at 40 °C giving 39 mg (29% yield) of the product as a yellow solid.  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  9.38 (m, 1 H), 9.08 (s, 1 H), 8.85 (d,  $J = 9$  Hz, 1 H), 8.67 (d,  $J = 5$  Hz, 1 H), 8.36 (d,  $J = 8$  Hz, 2 H), 8.32 (d,  $J = 8$  Hz, 2 H), 8.03 (m,  $J = 6$  Hz, 1 H), 7.99 (d,  $J = 8$  Hz, 2 H), 7.80 (br s, 1 H), 4.23 (m, 1 H), 3.45 (m, 1 H), 3.32 (m, 1 H), 3.29 (s, 3 H), 1.17 (d,  $J = 7$  Hz, 3 H);  $^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  165.8, 165.5, 154.9, 146.3, 138.2, 138.1, 137.5, 135.6, 134.3, 128.0, 126.9, 125.6, 123.0, 75.3, 58.4, 44.8, 17.6; MS (ESP)  $m/z$  407 ( $\text{M}^+ + 1$ ).

25

### Example 36

#### 3-Amino-N-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-2-pyrazinecarboxamide hydrochloride

The title compound was prepared as described for Example 35 using 1-(2-aminoethyl)pyrrolidine. The crude product was purified on silica using chloroform/methanol, (95:5), as eluent. Hydrochloride, yield 23%:  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  9.33 (s, 1 H), 8.67 (s, 1 H), 8.55 (d,  $J = 6$  Hz, 2 H), 8.0 (m, 3 H), 7.82 (d,  $J = 8$  Hz, 2 H), 3.83 (t,

30



$J = 6$  Hz, 4 H), 4.53 (t,  $J = 6$  Hz, 2 H), 3.23 (m, 2 H), 2.23 (m, 2 H), 2.09 (m, 2 H);  $^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ )  $\delta$  170.3, 165.4, 154.0, 145.5, 138.8, 137.5, 136.4, 133.6, 132.7, 128.2, 127.6, 125.7, 123.8, 55.0, 54.3, 36.6, 23.0; MS (ESP)  $m/z$  432 ( $\text{M}^+ + 1$ ).

5 **Example 37**

**3-Amino-*N*-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride**

Triethylamine (0.48 mL, 3.44 mmol) was added to a mixture of 3-amino-6-bromo-2-pyrazinecarboxylic acid (0.25 g, 1.15 mmol; described in: Ellingson, R. C.; Henry, R. L. *J. Am. Chem. Soc.* **1949**, 2798-2800), O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (0.405 g, 1.26 mmol) and 1-hydroxybenzotriazole (0.17 g, 1.26 mmol) in *N,N*-dimethylformamide/acetonitrile, (1:1, 5 mL). After stirring for 0.5 h at room temperature, 3-methoxyaniline (0.15 mL, 1.38 mmol) was added and the resulting mixture was stirred overnight at room temperature. Water (5-10 mL) was added and the precipitate was filtered off and washed with water to give 0.25 g (68% yield) of a yellow solid: MS (ESP)  $m/z$  323, 325 ( $\text{M}^+ + 1$ ).

The solid (0.19 g, 0.59 mmol) from previous step was dissolved in tetrahydrofuran/water, (5:1, 5 mL), together with 4-[(4-methylpiperazin-1-yl)sulfonyl]phenylboronic acid (0.25 g, 0.88 mmol), sodium carbonate (0.187 g, 1.76 mmol) and Pd(dppf) $\text{Cl}_2$  (14 mg, 0.018 mmol). The resulting mixture was stirred at 70 °C overnight ( $\text{N}_2$ -atmosphere). The mixture was evaporated onto silica and purified by chromatography using a gradient toluene/acetonitrile, (4:1 to 1:2), as the eluent to give 82 mg (29% yield) a yellow solid which was dried in vacuo at 40 °C. 48 mg of the base was dissolved in a methylene chloride/methanol mixture, (9:1), and hydrochloride acid in diethyl ether (0.13 mL, 1 M) was added. The precipitate was washed with diethyl ether and dried in vacuo to give 37 mg (63% yield) of the title compound:  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  9.05 (s, 1 H), 8.54 (d,  $J = 8$  Hz, 2 H), 7.86 (d,  $J = 8$  Hz, 2 H), 7.51 (m, 1 H), 7.44 (d,  $J = 8$  Hz, 1 H), 7.30 (m, 1 H), 6.75 (m, 1 H), 3.83 (d,  $J = 12$  Hz, 2 H), 3.78 (s, 3 H), 3.44 (m, 2 H), 3.16 (m, 2 H), 2.73 (m, 5 H);  $^{13}\text{C}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  164.3, 159.5, 154.7, 145.4, 140.6, 139.0, 136.2, 133.4, 129.4, 128.0, 126.4, 124.5, 113.3, 109.8, 106.8, 55.1, 51.5, 43.1, 41.9; MS (ESP)  $m/z$  483 ( $\text{M}^+ + 1$ ).

The following Examples, 38 – 41, were synthesized as described for Example 37.

**Example 38*****N*-(3-Acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride**

- Starting material: 3-acetylaniline. The title compound was purified by chromatography on silica gel using a gradient toluene/acetonitrile, (4:1 to 0:1), as the eluent, followed by formation of the hydrochloride salt, yield 2%:  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  10.7 (s, 1 H), 9.07 (s, 1 H), 8.57 (d,  $J$  = 8 Hz, 2 H), 8.43 (s, 1 H), 8.12 (d,  $J$  = 9 Hz, 1 H), 7.87 (d,  $J$  = 8 Hz, 2 H), 7.78 (d,  $J$  = 8 Hz, 1 H), 7.56 (d,  $J$  = 8 Hz, 1 H), 3.84 (d,  $J$  = 12 Hz, 2 H), 3.46 (d,  $J$  = 12 Hz, 2 H), 3.17 (m, 2 H), 2.75 (s, 3 H), 2.70 (m, 2 H), 2.62 (s, 3 H);  $^{13}\text{C}$  NMR (DMSO- $d_6$ )  $\delta$  197.6, 164.6, 154.7, 145.5, 140.6, 138.2, 137.2, 136.2, 133.2, 128.9, 128.0, 126.4, 125.7, 124.2, 120.4, 51.5, 43.0, 41.8, 26.8; MS (ESP)  $m/z$  495 ( $M^+$ +1).

**Example 39**

- 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[3-(trifluoromethyl)phenyl]-2-pyrazinecarboxamide hydrochloride**

- Starting material: 3-trifluoromethylaniline. Purification of the title compound by preparative HPLC (column: XTerra C8 19x300 mm, eluent: a water/acetonitrile/ammonium acetate gradient), followed by formation of the hydrochloride salt gave the title compound in 8% yield:  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  8.38 (s, 1 H), 7.71 (m, 2 H), 7.54 (m, 3 H), 7.26 (m, 1 H), 7.0 (m, 2 H), 3.52 (m, 4 H), 3.20 (m, 4 H), 2.95 (s, 3 H); MS (ESP)  $m/z$  521.

**Example 40**

- N*-[3-(Acetylamino)phenyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide**

- Starting material: 3-aminoacetanilide. The title compound was purified by chromatography on silica gel using a gradient toluene/acetonitrile, (4:1 to 0:1), as the eluent. Yield: 55% of the title compound as a yellow solid:  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  10.43, (s, 1 H), 10.01 (s, 1 H), 9.02 (s, 1 H), 8.50 (d,  $J$  = 8 Hz, 2 H), 8.09 (s, 1 H), 7.86 (br s, 1 H), 7.81 (d,  $J$  = 8 Hz, 2 H), 7.42 (m, 2 H), 7.30 (t,  $J$  = 8 Hz, 2 H), 2.96 (br s, 4 H), 2.45 (br s, 4 H), 2.21 (br s, 3 H), 2.06 (s, 3 H);  $^{13}\text{C}$  NMR (DMSO- $d_6$ )  $\delta$  168.3, 165.3, 154.7, 145.3, 140.3, 139.5, 138.0,

136.4, 133.8, 128.7, 127.9, 126.2, 124.5, 116.2, 115.2, 112.1, 53.3, 45.7, 45.5, 25.1; MS (ESP)  $m/z$  510 ( $M^+ + 1$ ).

#### Example 41

##### 5 **3-Amino-*N*-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide**

Starting material: 3-aminobenzenesulphonamide. Purification of the title compound by preparative HPLC (column: XTerra C8 19x300 mm, eluent: a water/acetonitrile/ammonium acetate gradient) gave 9% yield of the title compound as a yellow solid:  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  9.04 (s, 1 H), 8.51 (d,  $J = 8$  Hz, 2 H), 8.43 (s, 1 H), 8.01 (m, 1 H), 7.87 (br s, 2 H), 7.81 (d,  $J = 8$  Hz, 2 H), 7.61 (m, 2 H), 7.40 (s, 2 H), 2.94 (m, 4 H), 2.37 (m, 4 H), 2.14 (s, 3 H);  $^{13}\text{C}$  NMR (DMSO- $d_6$ )  $\delta$  164.7, 154.7, 145.6, 144.6, 140.2, 138.3, 136.6, 133.9, 129.2, 127.9, 126.3, 124.2, 124.1, 121.2, 118.1, 53.5, 45.7, 45.3; MS (ESP)  $m/z$  532 ( $M^+ + 1$ ).

#### Example 42

##### **4-{5-Amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid**

Pd(PPh<sub>3</sub>)<sub>4</sub> (1.05 g, 0.91 mmol) was added to a solution of 3-amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-carboxamide (2.0 g, 6.8 mmol), 4-carboxyphenylboronic acid (1.12 g, 6.7 mmol), and sodium carbonate (2.88 g, 27.2 mmol) in tetrahydrofuran/water, (1:1, 240 mL), and the resulting mixture was heated at 75°C for 16 days. The solvent was evaporated and the residue dissolved in water. The aqueous phase was washed with ethyl acetate and then neutralized (pH 7) using HCl (10% aq.). The formed crystals were filtered off and dried in vacuo to give 1.7 g (77% yield) of the title compound: MS (ES)  $m/z$  336 ( $M^+ + 1$ ).

#### Example 43

##### **4-Bromo-*N*-(2-ethoxyethyl)benzenesulfonamide**

(2-Ethoxyethyl)amine (0.178 g, 2.0 mmol) was added to a stirred solution of 4-bromobenzenesulfonyl chloride (0.256 g, 1.0 mmol) in tetrahydrofuran (10 mL) at 0 °C, followed by addition of *N*-ethyl-*N,N*-diisopropylamine (0.260 g, 2.0 mmol). The resulting mixture was stirred at 0 °C for 10 min, and was then allowed to return to room temperature. A saturated solution of NaHCO<sub>3</sub> (aq) was added and the phases were

separated, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated to give the crude product. Purification by column chromatography using ethyl acetate/heptane (1:10 to 1:1) as the eluent gave 0.278 g (90% yield) of the title compound: MS (ES) *m/z* 294 and 296 (*M*<sup>+</sup>+1).

5

#### Example 44

#### 3-Amino-6-(4-[[2-ethoxyethyl]amino]sulfonyl)phenyl)-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride

The title compound was prepared as described Example 17 using 4-bromo-*N*-(2-ethoxyethyl)benzenesulfonamide. Yield: 10 %: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 9.29 (d, *J* = 3 Hz, 1 H), 8.56 (s, 1 H), 8.54 (m, 1 H), 8.52 (m, 1 H), 8.01 (dd, *J* = 9, 6 Hz, 1 H), 7.98 (d, *J* = 9 Hz, 2 H), 7.71 (d, *J* = 9 Hz, 2 H), 3.45 (t, *J* = 5 Hz, 2 H), 3.41 (q, *J* = 7 Hz, 2 H), 3.07 (t, *J* = 5 Hz, 2 H), 1.05 (t, *J* = 7 Hz, 3 H); MS (ES) *m/z* 443 (*M*<sup>+</sup>+1).

15

#### Pharmaceutical compositions

According to one aspect of the present invention there is provided a pharmaceutical composition comprising a compound of formula I, as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

The composition may be in a form suitable for oral administration, for example as a tablet, for parenteral injection as a sterile solution or suspension. In general the above compositions may be prepared in a conventional manner using pharmaceutical carriers or diluents. Suitable daily doses of the compounds of formula I in the treatment of a mammal, including man, are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and about 0.001 to 250 mg/kg bodyweight at parenteral administration. The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a physician.

A compound of formula I, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, can be used on its own but will usually be administered in the form of a pharmaceutical composition in which the formula I compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable diluent or carrier.

- 5 Dependent on the mode of administration, the pharmaceutical composition may comprise from 0.05 to 99 %w (per cent by weight), for example from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

- 10 A diluent or carrier includes water, aqueous poly(ethylene glycol), magnesium carbonate, magnesium stearate, talc, a sugar (such as lactose), pectin, dextrin, starch, tragacanth, microcrystalline cellulose, methyl cellulose, sodium carboxymethyl cellulose or cocoa butter.

- 15 A composition of the invention can be in tablet or injectable form. The tablet may additionally comprise a disintegrant and/or may be coated (for example with an enteric coating or coated with a coating agent such as hydroxypropyl methylcellulose).

- 20 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula I, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a hereinbefore defined, with a pharmaceutically acceptable diluent or carrier.

- 25 An example of a pharmaceutical composition of the invention is an injectable solution containing a compound of the invention, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, as hereinbefore defined, and sterile water, and, if necessary, either sodium hydroxide or hydrochloric acid to bring the pH of the final composition to about pH 5, and optionally a surfactant to aid dissolution.

Liquid solution comprising a compound of formula I, as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, dissolved in water.

<u>Solution</u>	<u>mg/mL</u>
Compound X	5.0% w/v
Pure water	To 100%

5

### Medical use

Surprisingly, it has been found that the compounds defined in the present invention, as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, are well suited for inhibiting glycogen synthase kinase-3 (GSK3). Accordingly, the compounds of the present invention are expected to be useful in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 activity, i.e. the compounds may be used to produce an inhibitory effect of GSK3 in mammals, including man, in need of such prevention and/or treatment.

15

GSK3 is highly expressed in the central and peripheral nervous system and in other tissues. Thus, it is expected that compounds of the invention are well suited for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 in the central and peripheral nervous system. In particular, the compounds of the invention are expected to be suitable for prevention and/or treatment of conditions associated with especially, dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.

Other conditions are selected from the group consisting of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraceptive

medication, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

Further conditions are selected from the group consisting predemented states, Mild  
5 Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies and androgenetic alopecia.

10 One embodiment of the invention relates to the prevention and/or treatment of dementia and Alzheimer's Disease.

The dose required for the therapeutic or preventive treatment of a particular disease will necessarily be varied depending on the host treated, the route of administration  
15 and the severity of the illness being treated.

The present invention relates also to the use of a compound of formula I as defined hereinbefore, in the manufacture of a medicament for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

20

In the context of the present specification, the term "therapy" also includes "prevention" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

25 The invention also provides for a method of treatment and/or prevention of conditions associated with glycogen synthase kinase-3 comprising administering to a mammal, including man in need of such treatment and/or prevention a therapeutically effective amount of a compound of formula I, as hereinbefore defined.

#### **Non-medical use**

30 In addition to their use in therapeutic medicine, the compounds of formula I as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test

systems for the evaluation of the effects of inhibitors of GSK3 related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.

## 5 Pharmacology

### *Determination of ATP competition in Scintillation Proximity GSK3 $\beta$ Assay.*

#### *GSK3 $\beta$ scintillation proximity assay.*

The competition experiments were carried out in duplicate with 10 different concentrations of the inhibitors in clear-bottom microtiter plates (Wallac, Finland). A biotinylated peptide substrate, Biotin-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-Gly-Ser(PO<sub>3</sub>H<sub>2</sub>)-Pro-Gln-Leu (AstraZeneca, Lund), was added at a final concentration of 1  $\mu$ M in an assay buffer containing 1 mU recombinant human GSK3 $\beta$  (Dundee University, UK), 12 mM morpholinepropanesulfonic acid (MOPS), pH 7.0, 0.3 mM EDTA, 0.01%  $\beta$ -mercaptoethanol, 0.004 % Brij 35 (a natural detergent), 0.5 % glycerol and 0.5  $\mu$ g BSA/25  $\mu$ l. The reaction was initiated by the addition of 0.04  $\mu$ Ci [ $\gamma$ -<sup>33</sup>P]ATP (Amersham, UK) and unlabelled ATP at a final concentration of 1  $\mu$ M and assay volume of 25  $\mu$ l. After incubation for 20 minutes at room temperature, each reaction was terminated by the addition of 25  $\mu$ l stop solution containing 5 mM EDTA, 50  $\mu$ M ATP, 0.1 % Triton X-100 and 0.25 mg streptavidin coated Scintillation Proximity Assay (SPA) beads (Amersham, UK). After 6 hours the radioactivity was determined in a liquid scintillation counter (1450 MicroBeta Trilux, Wallac). The inhibition curves were analysed by non-linear regression using GraphPad Prism, USA. The K<sub>m</sub> value of ATP for GSK3 $\beta$ , used to calculate the inhibition constants (K<sub>i</sub>) of the various compounds, was 20  $\mu$ M.

25 The following abbreviations have been used:

MOPS	Morpholinepropanesulfonic acid
EDTA	Ethylenediaminetetraacetic acid
BSA	Bovin Serum Albumin
ATP	Adenosine Triphosphate
30 SPA	Scintillation Proximity Assay
GSK3	Glycogen synthase kinase 3



**Results**

Typical  $K_i$  values for the compounds of the present invention are in the range of about 0.001 to about 10,000 nM. Other values for  $K_i$  are in the range of about 0.001 to about 1000 nM. Further values for  $K_i$  are in the range of about 0.001 nM to about 300 nM.

## CLAIMS

1. A compound which is:

5 3-Amino-*N*-(3-nitrophenyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-*N*-1*H*-tetrazol-5-ylpyrazine-2-carboxamide;

10 *N*-[3-(Acetylamino)phenyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide;

3-Amino-*N*-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide;

15

as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof;

3-Amino-6-[4-({[(1*R*)-2-methoxy-1-methylethyl]amino}sulfonyl)phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

20

3-Amino-6-[4-({[(1*S*)-2-methoxy-1-methylethyl]amino}sulfonyl)phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

25 3-Amino-6-(4-{[(2-ethoxyethyl)amino}sulfonyl]phenyl)-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(2-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

30 3-Amino-*N*-(4-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[2-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

35

3-Amino-*N*-[3-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

40 3-Amino-*N*-(3-cyanophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(2-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(3-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

5 3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-1*H*-pyrazol-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[4-(aminocarbonyl)-1*H*-pyrazol-3-yl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

10 3-Amino-*N*-1*H*-imidazol-2-yl-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

15 3-Amino-6-[4-[[[(1-ethyl-3-piperidinyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

20 3-Amino-6-[4-[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[[[(3-methylbutyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

25 3-Amino-6-[4-[[[(1*S*)-2-methoxy-1-methylethyl]amino]carbonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-*N*-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

30 3-Amino-*N*-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

35 *N*-(3-Acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[3-(trifluoromethyl)phenyl]-2-pyrazinecarboxamide hydrochloride;

40 or as a free base or an alternative pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

2. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound according to claim 1 in association with pharmaceutically  
45 acceptable carriers or diluents.

3. The pharmaceutical formulation according to claim 2 for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.
- 5 4. A compound as defined in claim 1 for use in therapy.
5. Use of a compound according to claim 1 in the manufacture of a medicament for prevention and/or treatment of conditions associated with glycogen synthase kinase-3.
- 10 6. Use of a compound according to claim 1 in the manufacture of a medicament for prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.
- 15 7. The use according to claim 6 wherein the prevention and/or treatment is Alzheimer's Disease.
8. Use of a compound according to claim 1 in the manufacture of a medicament for  
20 prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraceptive medication, Type I and Type II  
25 diabetes, diabetic neuropathy and diabetes related disorders.
9. The use according to claim 8 wherein the prevention and/or treatment is Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.
- 30 10. Use of a compound according to claim 1 in the manufacture of a medicament for prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment

No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia.

5 11. A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound defined in claim 1.

10 12. A method of prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a  
15 compound defined in claim 1.


13. The method according to claim 12, wherein the prevention and/or treatment is Alzheimer's Disease.

20 14. A method of prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraceptive medication, Type I  
25 and Type II diabetes, diabetic neuropathy and diabetes related disorders comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound defined in claim 1.


15. The method according to claim 14, wherein the prevention and/or treatment is Type I  
30 and Type II diabetes, diabetic neuropathy and diabetes related disorders.

16. A method of prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound defined in claim 1.
17. A process for the preparation of a compound defined in claim 1 which falls under the general formula I, wherein Y, X, Z, P, Q, R, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, A, m and n are defined as in formula I, comprising of:


- A) de-halogen coupling of a compound of formula IV where Hal is halogen with a appropriate aryl species to give a compound of formula I:




B) amidation of a compound of formula VI wherein  $R^8$  is  $C_{1-6}$ alkyl or hydrogen with the appropriate amine:



C) amidation of a compound of formula XX, with the appropriate amine to give a compound of formula I:



D) amidation of a compound of formula XIX with the appropriate amine and treating with coupling reagents:



18. A compound which is 3-Amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-carboxamide  
as a free base or a salt, solvate or solvate of a salt thereof.

5

19. A compound which is:

4-Bromo-*N*-[(1*R*)-2-hydroxy-1-methylethyl]benzenesulfonamide;

4-Bromo-*N*-[(1*R*)-2-methoxy-1-methylethyl]benzenesulfonamide;

10

4-Bromo-*N*-[(1*S*)-2-methoxy-1-methylethyl]benzenesulfonamide;

4-Bromo-*N*-(1-ethyl-3-piperidinyl)benzenesulfonamide;

4-Bromo-*N,N*-bis(2-methoxyethyl)benzenesulfonamide;

15

4-Bromo-*N*-(3-methylbutyl)-benzenesulfonamide;

4-Bromo-*N*-(2-ethoxyethyl)benzenesulfonamide;

as a free base or a salt, solvate or solvate of a salt thereof.

20

20. A compound which is:

Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate;

Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate;

25

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid;

as a free base or a salt, solvate or solvate of a salt thereof.

21. A compound which is:

4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid;

30

4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid;


as a free base or a salt, solvate or solvate of a salt thereof.

22. A compound which is:



4-[2-(4-Bromo-2-fluorophenoxy)ethyl]morpholine as a free base or a salt, solvate or solvate of a salt thereof.

23. A compound which is:



wherein R, R<sup>3</sup>, P, X, Z, and m are as defined above, and wherein E and F are a methoxy group or hydrogen and G is a spacer chain containing atoms selected from oxygen and carbon as a free base or a salt, solvate or solvate of a salt thereof.

24. A compound which is:

3-{[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene;

Methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene;

as a free base or a salt, solvate or solvate of a salt thereof.

25. A compound which is 4-{5-Amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid as a free base or a salt, solvate or solvate of a salt thereof.

26. The use of the intermediates according to any one of claims 18 to 25 for the preparation of a compound of formula I as defined in claim 1.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2003/001956

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 401/12, C07D 401/14, C07D 403/12, C07D 403/14, A61K 31/497,  
 A61K 31/496, A61K 31/5377, A61P 25/00, A61P 3/10, 5/48, 15/18, 17/14 ✓  
 According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM.ABS.DATA, WPI DATA, EPO-INTERNAL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03004472 A1 (ASTRAZENECA AB), 16 January 2003 (16.01.2003)	1-17
	--	
A	WO 0168612 A2 (COCENSYS, INC.), 20 Sept 2001 (20.09.2001)	1-17
	-- -----	

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

19 April 2004

Date of mailing of the international search report

20-04-2004

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

EVA JOHANSSON/BS

Telephone No. +46 8 782 25 00

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/SE2003/001956**

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **11-16**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see extra sheet**
2. ☒ Claims Nos.: **3, 5, 11**  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
**see extra sheet**
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

**see extra sheet**

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
**1-17**

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE2003/001956

## Box II.1

Claims 11-16 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

## Box II.2

The expression "conditions associated with glycogen synthase kinase-3" in claims 3, 5 and 11 is not clear and concise and does not comply with PCT Articles 5 and 6 as it defines the conditions by the mechanism behind the conditions and does not mention the specific conditions. It is therefore not clear which conditions are comprised by these claims. The search has been performed on the general expression in some parts but has mainly been focused on the conditions named in claims 6-10.

## Box III

According to PCT Article 34 (3) (a-c) and Rule 13.2, an application shall relate to one invention only or to a group of inventions linked by one or more of the same or corresponding "special technical features", i.e. features that define a contribution which each of the inventions makes over the prior art. In order to consider that end products and intermediates represents one invention it is necessary that the essential structural elements of the end product also can be found in the intermediate. Claims 18-26 of the present application relate to a number of intermediates. These compounds are not considered to have enough structural similarity with the end products to fulfil the demands of unity. The compounds defined of the application have been divided into seven inventions according to the following:

- 1) Compounds according to formula I. Pharmaceutical formulations, use and methods involving these compounds and processes for the preparation of the compounds. Claims 1-17.
- 2) The compound 3-Amino-6-bromo- N- pyridin -3-ylpyrazine- 2- carboxamide and the use of this compound. Claims 18 and 26 partially.

.../...

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE2003/001956

3) The compounds

4- Bromo-*N*-[(1*R*)-2-hydroxy-1-methylethyl]benzenesulfonamide  
4-Bromo-*N*-[(1*R*)-2-methoxy-1-methylethyl]benzenesulfonamide  
4- Bromo-*N*-[(1*S*)-2-methoxy-1-methylethyl]benzenesulfonamide  
4- Bromo-*N*-(1-ethyl-3-piperidinyl)benzenesulfonamide  
4- Bromo-*N*,*N*-bis(2-methoxyethyl)benzenesulfonamide  
4- bromo-*N*-(3-methylbutyl)benzenesulfonamide  
4- bromo-*N*-(2-ethoxyethyl)benzenesulfonamide

and the use of these compounds. Claims 19 and 26 partially.

4) The compounds

Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate  
Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate  
3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid

and the use of these compounds. Claims 20 and 26 partially.

5) The compounds

4-[(4-Methylpiperazine-1-yl)sulfonyl]phenylboronic acid  
4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid

and the use of these compounds. Claims 21 and 26 partially

6) The compound

4-[2-(4-Bromo-2-fluorophenoxy)ethyl]morpholine and the use of this compound. Claims 22 and 26 partially.

7) Compounds comprising a polystyrene moiety (Formula XIX in the description) and the use of these compounds. Claims 23-24 and 26 partially.

8) The compound 4-{5-Amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid and the use of this compound. Claims 25 and 26 partially.

Only invention I (claims 1-17) has been searched.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

31/03/2004

International application No.

PCT/SE 2003/001956

WO	03004472	A1	16/01/2003	AU	1444702 A	15/05/2002
				SE	0102439 D	00/00/0000
<hr/>						
WO	0168612	A2	20/09/2001	AP	200202629 D	00/00/0000
				AU	4562001 A	24/09/2001
				CA	2400945 A	20/09/2001
				CN	1422254 T	04/06/2003
				EP	1265866 A	18/12/2002
				HU	0300466 A	28/07/2003
				IL	151417 D	00/00/0000
				JP	2003527376 T	16/09/2003
				NO	20024308 A	08/11/2002
				US	2002040025 A	04/04/2002

---